Novel GPI RUC-4 Shows Rapid, but Short Duration, Dose-Respondent Platelet Function Inhibition in Phase IIa Study
The novel small-molecule second-generation glycoprotein IIb/IIIa inhibitor (GPI) RUC-4 has shown dose-response high-grade inhibition of platelet function within 15 minutes in 27 ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention in its Phase IIa study.